JPWO2022093736A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022093736A5
JPWO2022093736A5 JP2023535666A JP2023535666A JPWO2022093736A5 JP WO2022093736 A5 JPWO2022093736 A5 JP WO2022093736A5 JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023535666 A JP2023535666 A JP 2023535666A JP WO2022093736 A5 JPWO2022093736 A5 JP WO2022093736A5
Authority
JP
Japan
Prior art keywords
fusion protein
dnaj
aav
tau
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548632A (ja
JP2023548632A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056539 external-priority patent/WO2022093736A1/en
Publication of JP2023548632A publication Critical patent/JP2023548632A/ja
Publication of JPWO2022093736A5 publication Critical patent/JPWO2022093736A5/ja
Publication of JP2023548632A5 publication Critical patent/JP2023548632A5/ja
Pending legal-status Critical Current

Links

JP2023535666A 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法 Pending JP2023548632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105472P 2020-10-26 2020-10-26
US63/105,472 2020-10-26
PCT/US2021/056539 WO2022093736A1 (en) 2020-10-26 2021-10-26 Compositions and methods for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2023548632A JP2023548632A (ja) 2023-11-17
JPWO2022093736A5 true JPWO2022093736A5 (https=) 2024-10-30
JP2023548632A5 JP2023548632A5 (https=) 2024-10-30

Family

ID=78676670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535666A Pending JP2023548632A (ja) 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法

Country Status (8)

Country Link
US (1) US20240025954A1 (https=)
EP (1) EP4232462A1 (https=)
JP (1) JP2023548632A (https=)
CN (1) CN117098771A (https=)
AU (1) AU2021367952A1 (https=)
CA (1) CA3199433A1 (https=)
TW (1) TW202233655A (https=)
WO (1) WO2022093736A1 (https=)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
JP2004502781A (ja) 2000-07-07 2004-01-29 パナシア ファーマシューティカルズ インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
PT2935326T (pt) * 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
US12162929B2 (en) 2018-02-19 2024-12-10 New York University Alpha-synuclein single domain antibodies
GB201902392D0 (en) * 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
EP4132955A2 (en) * 2020-04-10 2023-02-15 SOLA Biosciences LLC Compositions and methods for the treatment of protein aggregation disorders
BR112022021604A2 (pt) * 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43

Similar Documents

Publication Publication Date Title
JP2020522269A5 (https=)
JP2020505936A5 (https=)
JPWO2021113270A5 (https=)
JP6042825B2 (ja) 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
ES2230569T3 (es) Funciones accesorias para uso en la produccion de viriones aav recombinantes.
JP2021106619A5 (https=)
JP2018522529A5 (https=)
JP2018148927A5 (https=)
JP2021512649A5 (https=)
JP2007507223A5 (https=)
CN112041442A (zh) 用于逃避抗体的病毒载体的方法和组合物
JP2017536116A5 (https=)
JP2009526067A5 (https=)
JP2018531609A5 (https=)
TW201629225A (zh) 第九因子基因療法
JP7558535B2 (ja) アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
Bello et al. Isolation and evaluation of novel adeno-associated virus sequences from porcine tissues
JP2021523702A5 (https=)
JP2017529395A5 (https=)
JPWO2020069461A5 (https=)
JP2021534755A5 (https=)
BR112021005788A2 (pt) Métodos e composições para aumentar a expressão de proteínas e/ou tratar um distúrbio de haploinsuficiência
JP2020519294A5 (https=)
JP2021534794A5 (https=)
JPWO2022093736A5 (https=)